Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson of Recursion Pharmaceuticals sold 11,447 shares of Class A Common Stock on July 23, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 23, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at a weighted average price of $8.4774, with individual trades ranging from $7.94 to $8.68.
• Following the transaction, Borgeson directly owns 7,155,663 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a change in the director's confidence in the company.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.

Industry Context

Insider transactions are routinely monitored and reported, providing transparency to the market. Sales under 10b5-1 plans are common and allow insiders to diversify their holdings while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Monitoring insider trading activity is standard practice in the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and Roche also have executives who periodically execute trades under 10b5-1 plans.
• The volume of shares sold is relatively small compared to the total outstanding shares of Recursion Pharmaceuticals.

Stakeholder Impact

• The sale could have a minor impact on shareholder sentiment, but the existence of the 10b5-1 plan should mitigate concerns.

Key Dates